Grading Distress of Different Animal Models for Gastrointestinal Diseases Based on Plasma Corticosterone Kinetics.
corticosterone, stress, pancreatitis, liver fibrosis, pancreatic cancer, hypothalamic-pituitary-adrenal axis
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
03 Apr 2019
03 Apr 2019
Historique:
received:
13
02
2019
revised:
25
03
2019
accepted:
31
03
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
17
4
2019
Statut:
epublish
Résumé
Comparative studies for evaluating distress in established animal models are still rare. However, this issue is becoming more important as a consequence of worldwide appreciation of animal welfare. One good parameter for evaluating distress is the quantification of corticosterone. We hypothesized that not just the absolute value but also the duration of increased corticosterone concentration in the blood is an important aspect for evaluating animal distress. Therefore, we analyzed plasma corticosterone concentrations 30, 60, 120, and 240 min after induction of pancreatitis by cerulein, liver damage by carbon tetrachloride, liver damage by bile duct ligation, and after orthotopic injection of pancreatic cancer cells. We also evaluated corticosterone kinetics after injection of distinct carrier substances. Compared to phosphate buffered saline, dimethyl sulfoxide leads to dose-dependent higher and longer-lasting circulating corticosterone concentrations. In all disease models, we observed significantly increased corticosterone concentration 30 min after stress induction. However, the corticosterone kinetics differed among the animal models. Both the absolute value of corticosterone concentration and the duration correlated positively with the quantification of animal distress by a score sheet. This suggests that both variables of corticosterone kinetics might provide a solid basis for comparing and grading distress of different animal models
Identifiants
pubmed: 30987232
pii: ani9040145
doi: 10.3390/ani9040145
pmc: PMC6523747
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 321137804, ZE 712/1-1 and VO 450/15-1
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Br J Anaesth. 2000 Jul;85(1):109-17
pubmed: 10927999
Semin Liver Dis. 2001 Aug;21(3):437-51
pubmed: 11586471
Hypertension. 2002 Nov;40(5):768-73
pubmed: 12411475
Pancreas. 2003 Jul;27(1):58-66
pubmed: 12826907
J Neurosci. 2003 Jun 15;23(12):4850-7
pubmed: 12832507
Acta Endocrinol (Copenh). 1954;17(1-4):172-86
pubmed: 13227827
Toxicol Lett. 2004 Mar 1;147(2):153-9
pubmed: 14757319
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E823-8
pubmed: 15956051
J Appl Physiol (1985). 2006 Apr;100(4):1400-9
pubmed: 16239608
Neuroendocrinology. 2005;81(6):372-80
pubmed: 16276115
J Appl Physiol (1985). 2006 Jun;100(6):1867-75
pubmed: 16439512
Ann N Y Acad Sci. 1975 Jan 27;243:325-36
pubmed: 165761
Gut. 2007 Feb;56 Suppl 1:1-113
pubmed: 17303614
Brain Behav Immun. 2008 Jan;22(1):105-13
pubmed: 17890050
Cancer Treat Rev. 2009 Aug;35(5):431-6
pubmed: 19328630
Nat Methods. 2009 Apr;6(4):257-61
pubmed: 19333241
Comp Med. 2009 Jun;59(3):234-41
pubmed: 19619413
Br J Anaesth. 2009 Oct;103(4):511-7
pubmed: 19648157
Clin Exp Immunol. 1990 Mar;79(3):470-3
pubmed: 2156641
In Vivo. 2011 May-Jun;25(3):335-42
pubmed: 21576406
Eur J Pain. 2012 Jul;16(6):803-15
pubmed: 22337291
Braz J Med Biol Res. 2012 Apr;45(4):292-8
pubmed: 22450375
Gen Comp Endocrinol. 2012 Dec 1;179(3):406-13
pubmed: 23022994
Pharmacol Biochem Behav. 1990 Jul;36(3):515-9
pubmed: 2377652
Neuropsychopharmacology. 2014 Apr;39(5):1262-9
pubmed: 24280995
Exp Biol Med (Maywood). 2014 Jun;239(6):670-6
pubmed: 24719378
Front Behav Neurosci. 2014 May 15;8:166
pubmed: 24860451
Lab Anim. 2014 Oct;48(4):278-91
pubmed: 24958546
PLoS One. 2015 Feb 20;10(2):e0117503
pubmed: 25699675
Endocrinology. 2015 Aug;156(8):2843-53
pubmed: 26046806
Lancet. 2016 May 7;387(10031):1957-66
pubmed: 26948434
Am J Physiol Gastrointest Liver Physiol. 2016 Sep 1;311(3):G343-55
pubmed: 27418683
Oncotarget. 2016 Aug 30;7(35):56395-56407
pubmed: 27486761
Physiol Behav. 1987;40(6):775-9
pubmed: 2823307
Hepatology. 2017 Oct;66(4):1242-1257
pubmed: 28520165
Exp Biol Med (Maywood). 2017 Aug;242(14):1389-1397
pubmed: 28629226
Lab Anim. 2017 Dec;51(6):667
pubmed: 29160175
J Gastroenterol Hepatol. 2018 Jul;33(7):1312-1320
pubmed: 29424123
PLoS Biol. 2018 Feb 22;16(2):e2003693
pubmed: 29470495
Pharmacol Biochem Behav. 1988 Aug;30(4):1059-64
pubmed: 3227029
Exp Clin Endocrinol. 1988 May;91(2):241-3
pubmed: 3409974
Physiol Behav. 1986;37(4):559-61
pubmed: 3749319
Endocr Rev. 1984 Winter;5(1):1-24
pubmed: 6323158
Endocr Rev. 1984 Winter;5(1):25-44
pubmed: 6368214
Endocrinology. 1982 Oct;111(4):1286-91
pubmed: 6811257
Experientia. 1981 Mar 15;37(3):319-20
pubmed: 7195348
Cardiovasc Surg. 1996 Aug;4(4):483-91
pubmed: 8866086
J Pharmacol Exp Ther. 1997 Jan;280(1):284-91
pubmed: 8996208
Endocrinology. 1997 Sep;138(9):3842-8
pubmed: 9275073
Endocrinology. 1998 May;139(5):2407-13
pubmed: 9564852
Endocr Rev. 1998 Jun;19(3):269-301
pubmed: 9626555
J Pharmacol Toxicol Methods. 1998 Mar;39(2):71-3
pubmed: 9694164